Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fc-region variants with modified fcrn- and protein a-binding properties

a region variant and protein a-binding technology, applied in the field of igg fcregions, can solve the problems of reduced clearance, difficult production of bispecific antibodies in one expression cell line, poor yield of 12.5%, etc., and achieve the effect of avoiding systemic side effects

Inactive Publication Date: 2021-08-12
F HOFFMANN LA ROCHE INC
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text is talking about using an antibody that can target antigens in the eye and the rest of the body. The antibody should have a short life in the body after it passes through the barrier from the eye to the blood. This helps avoid side effects that may occur if the antibody is in the body for too long.

Problems solved by technology

The difficulties in isolating this desired bispecific antibody out of complex mixtures and the inherent poor yield of 12.5% at a theoretical maximum make the production of a bispecific antibody in one expression cell line extremely challenging.
The FcRn functions to salvage IgG from the lysosomal degradation pathway, resulting in reduced clearance and increased half-life.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Expression and Purification

[0599]Transient Transfections in HEK293-F System

[0600]The monospecific and bispecific antibodies are generated by transient transfection with the respective vectors (e.g. encoding the heavy and modified heavy chain, as well as the corresponding light and modified light chain) using the HEK293-F system (Invitrogen) according to the manufacturer's instruction. Briefly, HEK293-F cells (Invitrogen) growing in suspension either in a shake flask or in a stirred fermenter in serum-free FreeStyle™ 293 expression medium (Invitrogen) are transfected with a mix of the respective expression vectors and 293fectin™ or fectin (Invitrogen). For 2 L shake flask (Corning) HEK293-F cells are seeded at a density of 1*106 cells / mL in 600 mL and incubated at 120 rpm, 8% CO2. The day after the cells are transfected at a cell density of approx. 1.5*106 cells / mL with approx. 42 mL mix of A) 20 mL Opti-MEM (Invitrogen) with 600 μg total vector DNA (1 μg / mL) encoding the heavy or mo...

example 2

FeRn Chromatography

[0606]Coupling to Streptavidin Sepharose:

[0607]One gram streptavidin Sepharose (GE Healthcare) is added to the biotinylated and dialyzed receptor and incubated for two hours with shaking. The receptor derivatized Sepharose is filled in a 1 mL XK column (GE Healthcare).

[0608]Chromatography Using the FcRn Affinity Column:

[0609]Conditions:

[0610]column dimensions: 50 mm×5 mm

[0611]bed height: 5 cm

[0612]loading: 50 μg sample

[0613]equilibration buffer: 20 mM MES, with 150 mM NaCl, adjusted to pH 5.5

[0614]elution buffer: 20 mM Tris / HCl, with 150 mM NaCl, adjusted to pH 8.8

[0615]elution: 7.5 CV equilibration buffer, in 30 CV to 100% elution buffer, 10 CV elution buffer

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Herein is reported a heterodimeric polypeptide comprising a first polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, and a second polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first polypeptide comprises the mutations Y349C, T366S, L368A and Y407V (hole-chain) and the second polypeptide comprises the mutations S354C and T366W (knob-chain), and wherein the first polypeptide (hole-chain) comprises the mutations i) I253A or I253G, and ii) L314A or L314G or L314D, and wherein the first polypeptide and the second polypeptide are connected by one or more disulfide bridges, and wherein the CH3-domain of the first polypeptide and the CH3-domain of the second polypeptide both bind or both do not bind to protein A (numbering according to the Kabat EU index).

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. application Ser. No. 15 / 586,686, filed May 4, 2017 which is a continuation of International Application Number PCT / EP2015 / 075657, filed Nov. 4, 2015, which claims benefit under 35 U.S.C. § 119 to European Application Number 14192054.6, filed Nov. 6, 2014 which are incorporated herein by reference in their entirety.SEQUENCE LISTING[0002]This application hereby incorporates by reference the material of the electronic Sequence Listing filed concurrently herewith. The material in the electronic Sequence Listing is submitted as a text file entitled Sequence_Listing.txt created on Dec. 15, 2020 which has a file size of 58.0 KB, and is herein incorporated by reference in its entirety.FIELD OF THE INVENTION[0003]Herein are reported IgG Fc-regions that have been modified with respect to Fc-receptor as well as protein A binding.BACKGROUND OF THE INVENTION[0004]The demand for cost efficient production process...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/46C07K16/06C07K1/22C07K16/12
CPCC07K16/468C07K16/065C07K1/22C07K16/1271C07K2317/31C07K2317/524C07K2317/72C07K2319/00C07K2317/14C07K2317/526C07K2317/53C07K2317/71C07K2317/52C07K16/00A61P27/02A61P9/10A61K2039/505A61K39/395
Inventor SCHLOTHAUER, TILMAN
Owner F HOFFMANN LA ROCHE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com